Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 501–600 of 1,000
Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector
Srivastava, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.29017.asr · Cited by 24
“One review article supports the ‘‘revitalization of gene therapy,’’ 44 but I would suggest that the full potential of this approach is unlikely to be achieved by the first generation of viral vectors in general, and by AAV vectors in particular.”
Vranckx, L. S., Demeulemeester, J., Debyser, Z., & Gijsbers, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164167 · Cited by 24
Zhang, T., Guo, W., Zhang, C., Yu, J. X., Xu, J., Li, S., Tian, J., Wang, P. C., Xing, J., & Liang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03402 · Cited by 24
Xing, X., Pan, Y., & Yobaş, L. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03864 · Cited by 24
Duarte, S. M., Matian, P., Ma, S., Busuttil, R. W., & Coito, A. J. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.05.002 · Cited by 26
Santo, D., Mendonça, P. V., Lima, M. S., Cordeiro, R. A., Cabanas, L., Serra, A. C., Coelho, J. F. J., & Faneca, H. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00101 · Cited by 29
Cationic polymeric nanoformulation: Recent advances in material design for CRISPR/Cas9 gene therapy
Chen, K., Jiang, S., Hong, Y. Y., Li, Z., Wu, Y., & Wu, C. (2019) · Progress in Natural Science Materials International · doi:10.1016/j.pnsc.2019.10.003 · Cited by 28
The Pharmacology of Gene Therapy
Ylä‐Herttuala, S. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.007 · Cited by 24
“25 No 8 August transduction and production of enough therapeutic protein or RNA still represent the Achilles’ heel of current in vivo gene therapy approaches.(3)”
BackgroundToward Responsible Human Genome Editing
Hynes, R. O., Coller, B. S., & Porteus, M. H. (2017) · JAMA · doi:10.1001/jama.2017.4548 · Cited by 23
Bio-Orthogonal Mediated Nucleic Acid Transfection of Cells via Cell Surface Engineering
O’Brien, P. J., Elahipanah, S., Rogozhnikov, D., & Yousaf, M. N. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00132 · Cited by 28
Gene editing for inflammatory disorders
Ewart, D. T., Peterson, E. J., & Steer, C. J. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213454 · Cited by 26
Miyazaki, T., Uchida, S., Hatano, H., Miyahara, Y., Matsumoto, A., & Cabral, H. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.110028 · Cited by 21
Evaluation of dendronized gold nanoparticles as siRNAs carriers into cancer cells
Pędziwiatr‐Werbicka, E., Gorzkiewicz, M., Michlewska, S., Йонов, М., Shcharbin, D., Klajnert‐Maculewicz, B., González, C. E. P., Sánchez‐Nieves, J., Gómez, R., de la Mata, F. J., et al. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.114726 · Cited by 25
Nie, W., Wang, B., Mi, X., Chen, J., Yu, T., Miao, J., Lin, Y., Yang, T., Ran, M., Hong, Z., et al. (2021) · Small Methods · doi:10.1002/smtd.202001132 · Cited by 23
Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?
Deng, L., Liang, P., & Cui, H. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.03.007 · Cited by 27
Efficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides
Zeng, Y., Shen, M., Pattipeiluhu, R., Zhou, X., Zhang, Y., Bakkum, T., Sharp, T. H., Boyle, A. L., & Kros, A. (2023) · Nanoscale · doi:10.1039/d3nr02175k · Cited by 26
Generation of infectious recombinant Adeno-associated virus in Saccharomyces cerevisiae
Barajas, D., Aponte, J. J., Akeefe, H., Cinek, T., Peltier, J., & Gold, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173010 · Cited by 28
Wang, S., Li, C., Meng, Y., Qian, M., Jiang, H., Du, Y., Huang, R., & Wang, Y. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00326 · Cited by 23
Pinto, C., Silva, G. P. D. L., Ribeiro, A. S., Oliveira, M., Garrido, M., Bandeira, V., Nascimento, A., Coroadinha, A. S., Peixoto, C., Barbas, A., et al. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.05.016 · Cited by 22
Zou, Y., Shen, S., Karpus, A. O., Sun, H., Laurent, R., Caminade, A., Shen, M., Mignani, S. M., Shi, X., & Majoral, J. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01169 · Cited by 22
Targeted Therapies in Cancer Treatment: Unveiling the Latest Breakthroughs and Promising Approaches
Rai, V., Gupta, Y., Srivastava, S. P., Shukla, A., Bano, N., & Khan, S. (2024) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.6.26 · Cited by 26
Zhang, W., Jiao, Y., Zhang, Z., Zhang, Y., Yu, J., & Gu, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.013 · Cited by 26
A synthetic free fatty acid-regulated transgene switch in mammalian cells and mice
Liu, Y., Charpin-El-Hamri, G., Ye, H.-F., & Fussenegger, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky805 · Cited by 22
Николаевна, К. А., Malyarenko, O. S., Павленко, А. Ф., Dyshlovoy, S. A., Amsberg, G. V., Ermakova, S. P., & Leychenko, E. V. (2020) · Molecules · doi:10.3390/molecules25245979 · Cited by 22
“Although scientific and technological progress allowed the development of new approaches such as gene-therapy [3], stem cell transplantation [4], immunotherapy [5], and therapy by nanoparticles [6]”
BackgroundPlasmidHawk improves lab of origin prediction of engineered plasmids using sequence alignment
Wang, Q., Kille, B. L., Liu, T. R., Elworth, R. A. L., & Treangen, T. J. (2021) · Nature Communications · doi:10.1038/s41467-021-21180-w · Cited by 23
Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease
Odeh, H. M., Fare, C. M., & Shorter, J. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167220 · Cited by 26
Ma, Y., Kang, B., Li, S., Xie, G., Bi, J., Li, F., An, G., Liu, B., Li, J., Shen, Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.011 · Cited by 22
Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes
Guo, S., & Yi, C. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2023-0158 · Cited by 25
Engineering self-catabolic DNAzyme nanospheres for synergistic anticancer therapy
Chen, Y., Guo, Y., Wang, J., Liu, R., Yang, X., Wang, K., Pu, Y. D., Shi, H., & Huang, J. L. (2024) · Science China Chemistry · doi:10.1007/s11426-024-2095-6 · Cited by 23
Chromosome therapy: Potential strategies for the correction of severe chromosome aberrations
Plona, K. L., Kim, T. H., Halloran, K., & Wynshaw-Boris, A. J. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31530 · Cited by 23
“Barriers like nonselective targeting, incomplete efficiency, cellular toxicity, and immunogenic potential prevent complete and safe targeting within the cells [Naldini, 2015].”
BackgroundInfluentialHeller, P., Zhou, J., Weber, B., Hobernik, D., Bros, M., Schmid, F., & Barz, M. (2017) · Small · doi:10.1002/smll.201603694 · Cited by 22
Gene and Cell Doping: The New Frontier - Beyond Myth or Reality
Neuberger, E. W. I., & Simon, P. D. (2017) · Medicine and sport science/Medicine and sport · doi:10.1159/000465456 · Cited by 24
A mechanistic explanation of the inhibitory role of the protein corona on liposomal gene expression
Palchetti, S., Digiacomo, L., Giulimondi, F., Pozzi, D., Peruzzi, G., Ferri, G., Amenitsch, H. W., Cardarelli, F., Mahmoudi, M., & Caracciolo, G. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.183159 · Cited by 21
Multivariate data analysis in cell gene therapy manufacturing
Emerson, J., Kara, B., & Glassey, J. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107637 · Cited by 23
Zhao, Z., Wang, W., Wang, G., Huang, Z., Zhou, L., Li, L., Ou, Y., Huang, W., Zhang, X., Wu, C., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02242-1 · Cited by 21
“Recently, several new lung tumor elimination approaches have been proposed with improved treat-ment efficiency, such as immunotherapy [6], ferroptosis therapy [7] and gene therapy [8].”
BackgroundThe path to successful commercialization of cell and gene therapies: empowering patient advocates
Bauer, G., Abou‐El‐Enein, M., Kent, A., Poole, B. R., & Forte, M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.10.017 · Cited by 24
Psatha, N., Georgolopoulos, G., Phelps, S. R., & Papayannopoulou, T. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0048 · Cited by 23
Polyethylenimine-coated iron oxide magnetic nanoparticles for high efficient gene delivery
Anh, N. T. V., Abdelrasoul, G. N., Lin, D., Maadi, H., Tong, J., Chen, G., Wang, R., Anwar, A., Shoute, L. C. T., Fang, Q., et al. (2018) · Applied Nanoscience · doi:10.1007/s13204-018-0775-z · Cited by 21
“Effective methods for gene delivery have been responsible for the success of gene therapies for cancers or immunodeficient diseases (Naldini 2015).”
MethodTheranostic nanomedicine by surface nanopore engineering
Li, Z., Yu, L., Yang, T., & Chen, Y. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9297-5 · Cited by 21
Bulbake, U., Kommineni, N., Йонов, М., Bryszewska, M. J., & Khan, W. (2019) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2019.1567763 · Cited by 23
“Among them, gene therapy is a promising field for cancer therapy (Naldini 2015).”
BackgroundLevchenko, А., Nurgaliev, T., Kanapin, A. A., Samsonova, A. A., & Gainetdinov, R. R. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03990 · Cited by 21
“[105, 106] are potential approaches to treat psychiatric disorders.”
BackgroundGenome editing in pluripotent stem cells: research and therapeutic applications
Deleidi, M., & Yu, C. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.113 · Cited by 22
Evaluation of the Child With Developmental Impairments
van Karnebeek, C. (2018) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000564 · Cited by 25
Suppressing Tau Aggregation and Toxicity by an Anti-Aggregant Tau Fragment
Pir, G. J., Choudhary, B. C., Kaniyappan, S., Chandupatla, R., Mandelkow�, E., Mandelkow, E., & Wang, Y. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1326-z · Cited by 27
Moon, S. H., Lee, C. M., Park, S., & Nam, M. J. (2019) · Growth Factors · doi:10.1080/08977194.2019.1652399 · Cited by 21
“To address this major obstacle, vehicles have been developed to deliver therapeutic genes such as HGF that would permit long-term transgene expression (Motaln, Schichor, and Lah 2010; Naldini 2015).”
BackgroundMouse models in hematopoietic stem cell gene therapy and genome editing
Radtke, S., Humbert, O., & Kiem, H. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113692 · Cited by 22
Guimarães, M. R., de Medeiros, M. C., Rossi, D., Camilli, Â. C., Zanelli, C. F., Valentini, S. R., Spolidório, L. C., Kirkwood, K. L., & Rossa, C. (2020) · Clinical Oral Investigations · doi:10.1007/s00784-020-03644-3 · Cited by 24
“Gene therapy approaches using RNA interference are attractive particularly because of its high specificity, based on nucleotide complementarity and have been investigated in numerous clinical trials [38].”
BackgroundArumugasamy, S. K., Chellasamy, G., Murugan, N., Govindaraju, S., Yun, K., & Choi, M. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103245 · Cited by 22
Chowdary, P., Duran-Jimenez, B., Batty, P. A., Lowe, G., Jones, A., Pollard, D., Boyce, S., Motwani, J., Amirloo, B., Musgrave, K. M., et al. (2024) · Haemophilia · doi:10.1111/hae.15125 · Cited by 28
Animal toxins for channelopathy treatment
Kozlov, S. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.031 · Cited by 23
Targeted Nanoparticle‐Mediated Gene Therapy Mimics Oncolytic Virus for Effective Melanoma Treatment
Luo, L., Yang, Y., Du, T., Kang, T., Xiong, M., Cheng, H., Liu, Y., Wu, Y., Li, Y., Chen, Y., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201800173 · Cited by 21
Squeri, G., Passerini, L., Ferro, F., Laudisa, C., Tomasoni, D., Deodato, F., Donati, M. A., Gasperini, S., Aiuti, A., Bernardo, M. E., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.014 · Cited by 21
Self-citationMessenger RNA delivery by hydrazone-activated polymers
Juanes, M., Creese, O., Fernández‐Trillo, F., & Montenegro, J. (2019) · MedChemComm · doi:10.1039/c9md00231f · Cited by 20
Behl, T., Kaur, I., Kumar, A., Mehta, V., Zengin, G., & Arora, S. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200817164051 · Cited by 24
Endothelial Progenitor Cells as Shuttle of Anticancer Agents
Laurenzana, A., Margheri, F., Chillà, A., Biagioni, A., Margheri, G., Calorini, L., Fibbi, G., & Rosso, M. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.066 · Cited by 22
“From the 1980s to 1990s many studies have been performed to exploit gene therapy by using viral vectors carrying therapeutic genes 31 (Fig.”
Poly(lactide)-Based Materials Modified with Biomolecules: A Review
Świerczyńska, M., Kudzin, M. H., & Chruściel, J. J. (2024) · Materials · doi:10.3390/ma17215184 · Cited by 22
Runzer, C. D. T., Anand, S., Mota, C., Moroni, L., Plank, C., van Griensven, M., & Balmayor, E. R. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.019 · Cited by 19
Mohammadi, S., Akbari‐Birgani, S., Nikfarjam, N., & Rasekhian, M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104849 · Cited by 20
AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation
Wu, X., Yu, Y., Wang, M., Dai, D., Yin, J., Liu, W., Kong, D., Tang, S., Meng, M., Gao, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45383-z · Cited by 26
Wang, X., Herzog, R. W., Byrne, B. J., Kumar, S. R. P., Zhou, Q., Buchholz, C. J., & Biswas, M. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.005 · Cited by 19
Deng, H.-X., Wang, Y., Ding, Q.-R., Li, D., & Wei, Y.-Q. (2017) · Gene Therapy · doi:10.1038/gt.2017.62 · Cited by 19
Kasaraneni, N., Chamoun‐Emanuelli, A. M., Wright, G. A., & Chen, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-29253-5 · Cited by 21
ROS-responsive fluorinated polycations as non-viral gene vectors
Zhang, J.-H., Wang, W.-J., Zhang, J., Xiao, Y., Liu, Y., & Yu, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111666 · Cited by 19
Cancer terminator viruses (CTV): A better solution for viral‐based therapy of cancer
Emdad, L., Das, S. K., Wang, X., Sarkar, D., & Fisher, P. B. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26421 · Cited by 19
“A recent clinical trial used AAV8 vector (exhibited improved liver tropism and enhanced transduction efficiency in animal models) to deliver the hemophilia B transgene (Naldini, 2015).”
BackgroundIn vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy
Huang, Y., Cao, R. Y., Wang, S., Chen, X., Yü, P., & Zhang, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2558403 · Cited by 23
“145,146 Recent studies have shown that the gut microbiota is pivotal in regulating host immune responses and influencing the efficacy of cancer immunotherapy.”
Patel, M. R., Kozuch, S. D., Cultrara, C. N., Yadav, R., Huang, S., Samuni, U., Koren, J., Chiosis, G., & Sabatino, D. A. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02274 · Cited by 19
Jiang, D., Wang, M., Wang, T., Zhang, B., Liu, C., & Zhang, N. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s142966 · Cited by 18
“5,6 Till now, only two cancer-gene therapies have been approved in China, and none has been approved by the US Food and Drug Administration.”
BackgroundChitosan-Based Systems for Gene Delivery
Sharma, D., Arora, S., Rodrigues, B. D. S., Lakkadwala, S., Banerjee, A., & Singh, J. (2019) · Springer eBooks · doi:10.1007/978-981-15-0263-7_8 · Cited by 22
CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy
Pu, Y., Wu, W., Xiang, H., Chen, Y., & Xu, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101734 · Cited by 19
Guanidinylated bioresponsive poly(amido amine)s designed for intranuclear gene delivery
Ding, P., Yu, J., Zhang, J., Xing, H., Yang, Z. L., Cai, C., Zhang, C., Zhao, X., Yang, L., & Wei, M. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s109406 · Cited by 18
“4 Currently, the two most popular nonviral gene delivery systems have been widely used in laboratory and clinical studies: 1) using electroporation to transfect cells, 5–7 and 2) cationic polymers, such as cationic liposomes and polyethylenimines (PEIs).”
Polymeric prodrug for bio-controllable gene and drug co-delivery
Jia, H., Chen, S., Zhuo, R., Feng, J. X., & Zhang, X. (2016) · Science China Chemistry · doi:10.1007/s11426-016-0230-9 · Cited by 18
The state of gene therapy research in Africa, its significance and implications for the future
Arbuthnot, P. B., Maepa, M. B., Ely, A., & Pepper, M. S. (2017) · Gene Therapy · doi:10.1038/gt.2017.57 · Cited by 21
“2, 3 The technology is, however, not yet widely used in clinical settings, and licenses have usually only been granted in particular countries.”
BackgroundProspects of Gene Therapy to Treat Melanoma
Menezes, M. E., Talukdar, S., Wechman, S. L., Das, S. K., Emdad, L., Sarkar, D., & Fisher, P. B. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.007 · Cited by 18
Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma
Kamimura, K., Yokoo, T., Abé, H., Sakai, N., Nagoya, T., Kobayashi, Y., Ohtsuka, M., Miura, H., Sakamaki, A., Kamimura, H., et al. (2020) · Cancers · doi:10.3390/cancers12020472 · Cited by 22
Yan, X., Lin, L., Li, S., Wang, W., Chen, B., Jiang, S., Liu, S., Ma, X., & Yu, X. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.125171 · Cited by 19
Pereira‐Silva, M., Jarak, I., Paiva‐Santos, A. C., Veiga, F., & Figueiras, A. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105461 · Cited by 19
Nuclear targeting Subcellular-delivery nanosystems for precise cancer treatment
Du, W., Zhang, L., Li, X., Ling, G., & Zhang, P. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121735 · Cited by 18
Genome editing technologies to fight infectious diseases
Trevisan, M., Palù, G., & Barzon, L. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1400379 · Cited by 18
Current Status of Nonviral Vectors for Gene Therapy in China
Liu, L., Yang, H. J., Men, K., He, Z., Luo, M., Qian, Z., Wei, X., & Wei, Y. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.226 · Cited by 19
“Gene therapy has shown remarkable therapeutic benefits, excellent safety, and was considered to have “returned to center stage” in recent years.(5) Current gene transfection methods include viral vector systems for gene transduction,(6) direct microinjection systems,(7) and nonviral vector systems; nonviral vectors ar…”
Photoacoustic transfection of DNA encoding GFP
Silva, A. D., Serpa, C., & Arnaut, L. G. (2019) · Scientific Reports · doi:10.1038/s41598-018-37759-1 · Cited by 20
Biosilicified oncolytic adenovirus for cancer viral gene therapy
Kong, H., Zhao, R., Zhang, Q., Iqbal, M. Z., Lü, J., Zhao, Q. D., Luo, D., Feng, C., Zhang, K., Liu, X., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00681e · Cited by 18
Kumari, M., Liu, C., Wu, W., & Wang, C. (2021) · Journal of Materials Science · doi:10.1007/s10853-020-05648-6 · Cited by 18
Mechanism of action of Nrf2 and its related natural regulators in rheumatoid arthritis
Ma, K., Miao, L., Li, B., Yu, W., Liu, F., Liu, K., Li, Y., Huang, C., & Yang, Z. G. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-05221-w · Cited by 22
“However, due to its potential to treat the disease at its source, it may be a new possibility [146].”
Wang, T., Chen, Q., Lu, H., Li, W., Li, Z., Ma, J., & Gao, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00355 · Cited by 19
Emerging Therapeutic Approaches for Diamond Blackfan Anemia
Aspesi, A., Borsotti, C., & Follenzi, A. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181109124538 · Cited by 23
“In particular, important results have been achieved by ex vivo gene transfer into HSCs for the treatment of hematological and neurodegenerative disorders [41].”
BackgroundLaser‐assisted nucleic acid delivery: A systematic review
Hosseinpour, S., & Walsh, L. J. (2020) · Journal of Biophotonics · doi:10.1002/jbio.202000295 · Cited by 17
Wang, H., Zhou, Z., Lin, W., Qian, Y., He, S., & Wang, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11630-7 · Cited by 19
“In recent times, hBMSCs have gained attention as targeted vectors for gene therapy in HNSCC due to their inherent homing, trafficking potential, and regenerative capacity [3, 4].”
BackgroundTemporal Airy pulses control cell poration
Courvoisier, S., Götte, N., Zielinski, B., Winkler, T., Sarpe, C., Senftleben, A., Bonacina, L., Wolf, J., & Baumert, T. (2016) · APL Photonics · doi:10.1063/1.4948367 · Cited by 17
Liposomal-Based Therapeutic Carriers for Vaccine and Gene Delivery
Rahman, M., Beg, S., Verma, A., Anwar, F., Samad, A., & Kumar, V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809717-5.00005-1 · Cited by 17
Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis
Biasco, L., Rothe, M., Schott, J. W., & Schambach, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.009 · Cited by 19
Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin
Reckzeh, K., Kizilkaya, H. S., Helbo, A. S., Estruch, M., Deslauriers, A. G., Grover, A., Rapin, N., Asmar, F., Grønbæk, K., Porse, B. T., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015743 · Cited by 16
Destabilizing Domains Enable Long-Term and Inert Regulation of GDNF Expression in the Brain
Quintino, L., Namislo, A., Davidsson, M., Breger, L. S., Kavanagh, P., Avallone, M., Wettergren, E. E., Isaksson, C., & Lundberg, C. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.008 · Cited by 18
Ma, J., Su, C., Hu, S., Chen, Y., Shu, Y., Yue, D., Zhang, B., Qi, Z., Li, S., Wang, X., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.013 · Cited by 19
Branco, A., Bucar, S., Moura-Sampaio, J., Lilaia, C., Cabral, J. M. S., Fernandes‐Platzgummer, A., & da Silva, C. L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.573282 · Cited by 17
“…fingerprints and their regressions may be used for purposes other than the expansion of UCB-derived HSPC for HCT. Revived interest in autologous gene therapy has consolidated the application of expanded adult HSPC for treatment of genetic hematological diseases (Naldini, 2015; Dunbar et al., 2018).”
MethodLaser‐assisted targeted gene delivery to degenerated retina improves retinal function
Batabyal, S., Kim, S. H., Wright, W. W., & Mohanty, S. K. (2020) · Journal of Biophotonics · doi:10.1002/jbio.202000234 · Cited by 19
Structures of malonic acid diamide/phospholipid composites and their lipoplexes
Janich, C., Taßler, S., Meister, A., Hause, G., Schäfer, J., Bakowsky, U., Brezesinski, G., & Wölk, C. (2016) · Soft Matter · doi:10.1039/c6sm00807k · Cited by 18
Yang, J., Zhang, J., Liu, Y., Shi, Z., Han, H., & Li, Q. (2019) · Biomaterials Science · doi:10.1039/c9bm00394k · Cited by 17
Tailoring non-viral delivery vehicles for transporting genome-editing tools
Sun, W., & Gu, Z. (2016) · Science China Materials · doi:10.1007/s40843-016-5154-4 · Cited by 18
Branch-PCR constructed TP53 gene nanovector for potential cancer therapy
Cheng, L., Deng, H., Ma, D., Zhai, B., Zhang, Q., Li, L., & Xi, Z. (2018) · Chemical Communications · doi:10.1039/c8cc05066j · Cited by 16
Andreou, T., Williams, J. M., Brownlie, R. J., Salmond, R. J., Watson, E., Shaw, G. C., Melcher, A. A., Wurdak, H., Short, S. C., & Lorger, M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001143 · Cited by 19
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.